Molecular Partners (MOLN) Stock Statistics & Valuation Metrics

Molecular Partners has a market cap or net worth of $159.56M. The enterprise value is $41.99M.

Molecular Partners has 40,374,640 shares outstanding. The number of shares has decreased by -2.65% in one year.

Molecular Partners’s return on equity (ROE) is -0.77 and return on invested capital (ROIC) is -62.98%.

The current PE Ratio of Molecular Partners is ―. Molecular Partners’s PEG ratio is -0.56.

In the last 12 months, Molecular Partners had revenue of 0.00 and earned -61.65M in profits. Earnings per share was -1.65.

In the last 12 months, operating cash flow was -53.80M and capital expenditures -333.55K, giving a free cash flow of -54.13M billion.

Molecular Partners pays an annual dividend of ―, resulting in a dividend yield of ―

Molecular Partners upcoming earnings date is Aug 25, 2026, TBA (Confirmed).

Molecular Partners as a current ratio of 8.79, with Debt / Equity ratio of 4.89%

In the past 12 months, Molecular Partners has paid 2.00K in taxes.

Molecular Partners EV to EBITDA ratio is -0.84, with an EV/FCF ratio of -0.96.

Molecular Partners has $78.53M in cash and marketable securities with $3.33M in debt, giving a net cash position of $75.20M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Molecular Partners is $12.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy